Impax Laboratories Inc. (IPXL)

17.90
0.22 1.24
NYSE : Health Technology
Prev Close 17.68
Open 17.72
Day Low/High 17.50 / 18.29
52 Wk Low/High 13.47 / 18.29
Volume 839.29K
Avg Volume 916.90K
Exchange NYSE
Shares Outstanding 73.87M
Market Cap 1.35B
EPS -6.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
31 Drugs Facing FDA Approval in 2012-2013

31 Drugs Facing FDA Approval in 2012-2013

An updated calendar listing FDA drug approval decisions and advisory panels for the remainder of 2012 and early 2013

8 Stocks Soaring With Unusual Volume

8 Stocks Soaring With Unusual Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

Impax Laboratories Management Discusses Q2 2012 Results - Earnings Call Transcript

Impax Laboratories Management Discusses Q2 2012 Results - Earnings Call Transcript

Impax Laboratories Management Discusses Q2 2012 Results - Earnings Call Transcript

Impax Laboratories Reports Second Quarter 2012 Adjusted EPS Increased To $0.60; GAAP EPS Increased To $0.27

Impax Laboratories Reports Second Quarter 2012 Adjusted EPS Increased To $0.60; GAAP EPS Increased To $0.27

Impax Laboratories, Inc. (NASDAQ: IPXL) today reported second quarter 2012 financial results.

7 Stocks Rising on Heavy Volume

7 Stocks Rising on Heavy Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

Impax Laboratories Schedules Conference Call And Webcast For Second Quarter 2012 Financial Results

Impax Laboratories Schedules Conference Call And Webcast For Second Quarter 2012 Financial Results

Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that its second quarter 2012 financial results will be released before the market opens on Tuesday, July 31, 2012 and will be available on Impax’s Web site...

Impax Laboratories Announces Resignation Of Arthur A. Koch

Impax Laboratories Announces Resignation Of Arthur A. Koch

Impax Laboratories, Inc. (NASDAQ: IPXL) (the “Company”) today announced that Arthur A.

Impax Laboratories Enters Into Development, Supply And Distribution Agreement With TOLMAR, Inc.

Impax Laboratories Enters Into Development, Supply And Distribution Agreement With TOLMAR, Inc.

Impax Laboratories, Inc. (NASDAQ: IPXL) and TOLMAR, Inc.

Impax Laboratories To Present At The Wells Fargo Securities Healthcare Conference

Impax Laboratories To Present At The Wells Fargo Securities Healthcare Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Wells Fargo Securities 2012 Healthcare Conference on Tuesday, June 19, at 2:30 p.

Impax Laboratories To Present At The Goldman Sachs Annual Global Healthcare Conference

Impax Laboratories To Present At The Goldman Sachs Annual Global Healthcare Conference

Impax Laboratories, Inc. (NASDAQ:IPXL) today announced that the Company will present at the Goldman Sachs 33 rd Annual Global Healthcare Conference on Thursday, June 7, at 10:00 a.

Impax Laboratories Announces Voting Results From 2012 Annual Meeting Of Stockholders

Impax Laboratories Announces Voting Results From 2012 Annual Meeting Of Stockholders

Impax Laboratories, Inc. (NASDAQ: IPXL) held its 2012 Annual Meeting of Stockholders today in San Mateo, California.

Impax Laboratories To Present At The Bank Of America Merrill Lynch 2012 Health Care Conference

Impax Laboratories To Present At The Bank Of America Merrill Lynch 2012 Health Care Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Bank of America Merrill Lynch 2012 Health Care Conference on Wednesday, May 16, at 10:40 a.

5 Stocks Setting Up to Break Out

5 Stocks Setting Up to Break Out

These stocks look poised to break out and trade higher from current levels.

Data From ASCEND-PD Phase III Study Of IPX066 To Be Presented At The American Academy Of Neurology Conference

Data From ASCEND-PD Phase III Study Of IPX066 To Be Presented At The American Academy Of Neurology Conference

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc.

Impax Laboratories Confirms Patent Challenge Relating To Generic GRALISE® 300 Mg And 600 Mg

Impax Laboratories Confirms Patent Challenge Relating To Generic GRALISE® 300 Mg And 600 Mg

Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of the patents listed in the Orange Book in connection with Gralise® (gabapentin tablets, 300 mg and 600 mg).

Impax Laboratories Schedules Conference Call And Webcast For First Quarter 2012 Financial Results

Impax Laboratories Schedules Conference Call And Webcast For First Quarter 2012 Financial Results

Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that its first quarter 2012 financial results will be released before the market opens on Tuesday, May 1, 2012 and will be available on Impax’s Web site at...

Impax Laboratories Enters Into Development, Supply And Distribution Agreement With TOLMAR, Inc.

Impax Laboratories Enters Into Development, Supply And Distribution Agreement With TOLMAR, Inc.

Impax Laboratories, Inc. (NASDAQ: IPXL) and TOLMAR, Inc.

Impax Laboratories To Present At The Cowen And Company Health Care Conference

Impax Laboratories To Present At The Cowen And Company Health Care Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Cowen and Company Health Care Conference on Tuesday, March 6, at 11:20 a.

Impax Laboratories Fourth Quarter 2011 EPS Increases 74% To $0.33

Impax Laboratories Fourth Quarter 2011 EPS Increases 74% To $0.33

Impax Laboratories, Inc. (NASDAQ: IPXL) today reported fourth quarter and full year ended December 31, 2011 financial results.

Impax Laboratories To Present At The RBC Capital Markets’ Healthcare Conference

Impax Laboratories To Present At The RBC Capital Markets’ Healthcare Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the RBC Capital Markets’ Healthcare Conference on Wednesday, February 29, at 12:00 p.

FDA Accepts Impax Pharmaceuticals NDA Filing For IPX066 For The Treatment Of Idiopathic Parkinson’s Disease

FDA Accepts Impax Pharmaceuticals NDA Filing For IPX066 For The Treatment Of Idiopathic Parkinson’s Disease

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc.

Impax Laboratories Provides Update On Status Of Warning Letter Resolution For Its Hayward Facility

Impax Laboratories Provides Update On Status Of Warning Letter Resolution For Its Hayward Facility

Impax Laboratories, Inc. (NASDAQ: IPXL) today provided an update on the status of its resolution of the previously disclosed warning letter issued by the U.

Impax Rises On Unusually High Volume (IPXL)

Impax Rises On Unusually High Volume (IPXL)

Impax Laboratories (Nasdaq:IPXL) is trading at unusually high volume Thursday with 2.2 million shares changing hands. It is currently at four times its average daily volume and trading up $1.40 (+6.8%).

8 Stocks Rising on Huge Volume

8 Stocks Rising on Huge Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

Impax Pharmaceuticals Licenses Exclusive U.S. Commercialization Rights To Zomig® (zolmitriptan) From AstraZeneca

Impax Pharmaceuticals Licenses Exclusive U.S. Commercialization Rights To Zomig® (zolmitriptan) From AstraZeneca

Impax Pharmaceuticals, the branded products business unit of Impax Laboratories, Inc.

Impax Laboratories Schedules Conference Call And Webcast For Fourth Quarter And Full Year 2011 Financial Results

Impax Laboratories Schedules Conference Call And Webcast For Fourth Quarter And Full Year 2011 Financial Results

Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that its fourth quarter and full year 2011 financial results will be released before the market opens on Tuesday, February 28, 2012 and will be available on...

UBS: 8 Pharma Stocks to Watch

UBS: 8 Pharma Stocks to Watch

UBS Investment Research recently highly these stocks in its review of the pharamaceutical sector.

Impax Laboratories Inc. Stock Upgraded (IPXL)

Impax Laboratories Inc. Stock Upgraded (IPXL)

Impax Laboratories (Nasdaq:IPXL) has been upgraded by TheStreet Ratings from a hold to buy.

Impax Laboratories To Present At The J.P. Morgan Healthcare Conference

Impax Laboratories To Present At The J.P. Morgan Healthcare Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the J.

Impax Pharmaceuticals Submits New Drug Application For IPX066 In Parkinson’s Disease

Impax Pharmaceuticals Submits New Drug Application For IPX066 In Parkinson’s Disease

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc.